United States Preventive Services Task Force

Last updated

The United States Preventive Services Task Force (USPSTF) is "an independent panel of experts in primary care and prevention that systematically reviews the evidence of effectiveness and develops recommendations for clinical preventive services". [1] The task force, a volunteer panel of primary care clinicians (including those from internal medicine, pediatrics, family medicine, obstetrics and gynecology, nursing, and psychology) with methodology experience including epidemiology, biostatistics, health services research, decision sciences, and health economics, is funded, staffed, and appointed by the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality. [2] [3]

Contents

Intent

The USPSTF evaluates scientific evidence to determine whether medical screenings, counseling, and preventive medications work for adults and children who have no symptoms.

Methods

The methods of evidence synthesis used by the Task Force have been described in detail. [4] In 2007, their methods were revised. [5] [6]

No weight given to cost-effectiveness

The USPSTF explicitly does not consider cost as a factor in its recommendations, and it does not perform cost-effectiveness analyses. [7] American health insurance groups are required to cover, at no charge to the patient, any service that the USPSTF recommends, regardless of how much it costs or how small the benefit is. [8]

Grade definitions

The task force assigns the letter grades A, B, C, D, or I to each of its recommendations, and includes "suggestions for practice" for each grade. The Task Force also defined levels of certainty regarding net benefit. [9]

GradeResultMeaning
Grade ARecommendedThere is high certainty that the net benefit is substantial.
Grade BRecommendedThere is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial.
Grade CNo recommendationClinicians may provide the service to selected patients depending on individual circumstances. However, for most individuals without signs or symptoms there is likely to be only a small benefit.
Grade DRecommended againstThe Task Force recommends against this service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits.
I statementInsufficient evidenceThe current evidence is insufficient to assess the balance of benefits and harms.

Levels of certainty vary from high to low according to the evidence.

The USPSTF has evaluated many interventions for prevention and found several have an expected net benefit in the general population. [10]

Breast cancer screening

In 2009, the USPSTF updated its advice for screening mammograms. [12] Screening mammograms, or routine mammograms, are X-rays given to apparently healthy women with no symptoms or evidence of breast cancer in the hope of detecting the disease in an early, easily treatable stage. The advice about using mammography in the presence of symptoms (such as a lump in the breast that can be felt) is unchanged.

The previous advice was for all women over the age of 40 to receive a mammogram every one to two years. [13] The new advice is more detailed. For women between the ages of 50 and 74, they have recommended routine mammograms once every two years in the absence of symptoms. Most American women who are diagnosed with breast cancer are diagnosed after age 60. [14] [15]

The USPSTF declared that there is insufficient evidence to make any statement about the use of mammograms in women over the age of 75, as very little research has been performed in this age group.

The Task Force made no recommendation about routine mammography to screen asymptomatic women aged 40 to 49 years for breast cancer. Patients in this age group should be educated about the risks and benefits of screening, and the decision whether to screen or not should be based on the individual situation and preferences. [16] The old advice was based on "weak" evidence for this age group. [13] The new advice is based on improved scientific evidence about the benefits and harms associated with mammography and is consistent with recommendations by the World Health Organization and other major medical bodies. Their recommendation against routine, suspicion-less mammograms for younger women does not change the advice for screening women at above-average risk for developing breast cancer or for testing women who have a suspicious lump or any other symptoms that might be related to breast cancer.

The change in the recommendation for younger women has been criticized by some physicians and cancer advocacy groups, such as Otis Brawley, the chief medical officer for the American Cancer Society, [17] and praised by physicians and medical organizations that support individualized and evidence-based medicine, such as Donna Sweet, the former chair of the American College of Physicians, who currently serves on its Clinical Efficacy Assessment Subcommittee. [18]

The USPSTF recommendation, which focuses solely on clinical effectiveness without regard to cost, [19] formally reduces the grade given for evidence quality from "B" to "C" (limited evidence prevents a one-size-fits-all recommendation) for routine mammograms in women under the age of 50. [20] With a grade C recommendation, physicians are required to consider additional factors, such as the individual woman's personal risk of breast cancer. Pending health care legislation would require insurance companies to cover any and all preventive services that receive an "A" or "B" grade, but permit them to use discretion on preventive services that receive a worse grade. [20]

The Vitter amendment to the Mikulski amendment to pending legislation in the U.S. Senate instructs insurers to disregard the task force's recommendation against frequent routine mammograms in asymptomatic younger women, and requires them to provide free annual mammograms, even for low-risk women, based on the outdated 2002 report. [20] This proposal is not yet law and may change. [ needs update ] The efforts by politicians to reject the committee's scientific findings have been condemned as an example of unwarranted political interference in scientific research. [19]

Prostate cancer screening

In the current recommendation published in 2018, the Task Force recommended that prostate-specific antigen (PSA)-based screening for prostate cancer screenings be an individual decision for men between the ages of 55 to 69. [21] In 2018 the Task Force gave PCa screening a C recommendation. [21]

A final statement published in 2018 recommends basing the decision to screen on shared decision making in those 55 to 69 years old. [22] It continues to recommend against screening in those 70 and older. [22]

History

The initial USPSTF was created in 1984 as a 5 year appointment to "develop recommendations for primary care clinicians on the appropriate content of periodic health examinations" and was modelled on the Canadian Task Force on Preventive Health Care, established in 1976. [23] This initial 5 year project concluded in 1989 with the release of their report, the Guide to Clinical Preventive Services. In July 1990, the Department of Health and Human Services reconstituted the Task Force to continue and update these scientific assessments of preventive services. [24]

Related Research Articles

<span class="mw-page-title-main">Breast cancer</span> Cancer that originates in mammary glands

Breast cancer is a cancer that develops from breast tissue. Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, milk rejection, fluid coming from the nipple, a newly inverted nipple, or a red or scaly patch of skin. In those with distant spread of the disease, there may be bone pain, swollen lymph nodes, shortness of breath, or yellow skin.

<span class="mw-page-title-main">Mammography</span> Process of using low-energy X-rays to examine the human breast for diagnosis and screening

Mammography is the process of using low-energy X-rays to examine the human breast for diagnosis and screening. The goal of mammography is the early detection of breast cancer, typically through detection of characteristic masses or microcalcifications.

<span class="mw-page-title-main">Breast self-examination</span> Physical and visual inspection of ones own breasts

Breast self-examination (BSE) is a screening method used in an attempt to detect early breast cancer. The method involves the woman herself looking at and feeling each breast for possible lumps, distortions or swelling.

<span class="mw-page-title-main">Rectal examination</span> Medical assessment or diagnostic procedure

Digital rectal examination (DRE), also known as a prostate exam, is an internal examination of the rectum performed by a healthcare provider.

<span class="mw-page-title-main">Physical examination</span> Process by which a medical professional investigates the body of a patient for signs of disease

In a physical examination, medical examination, clinical examination, or medical checkup, a medical practitioner examines a patient for any possible medical signs or symptoms of a medical condition. It generally consists of a series of questions about the patient's medical history followed by an examination based on the reported symptoms. Together, the medical history and the physical examination help to determine a diagnosis and devise the treatment plan. These data then become part of the medical record.

<span class="mw-page-title-main">Preventive healthcare</span> Prevention of the occurrence of diseases

Preventive healthcare, or prophylaxis, is the application of healthcare measures to prevent diseases. Disease and disability are affected by environmental factors, genetic predisposition, disease agents, and lifestyle choices, and are dynamic processes that begin before individuals realize they are affected. Disease prevention relies on anticipatory actions that can be categorized as primal, primary, secondary, and tertiary prevention.

<span class="mw-page-title-main">Screening (medicine)</span> Brief medical evaluation to detect unnoticed health problems

Screening, in medicine, is a strategy used to look for as-yet-unrecognised conditions or risk markers. This testing can be applied to individuals or to a whole population without symptoms or signs of the disease being screened.

Prostate cancer screening is the screening process used to detect undiagnosed prostate cancer in men without signs or symptoms. When abnormal prostate tissue or cancer is found early, it may be easier to treat and cure, but it is unclear if early detection reduces mortality rates.

Ductal carcinoma <i>in situ</i> Pre-cancerous breast lesion

Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive cancerous lesion of the breast. DCIS is classified as Stage 0. It rarely produces symptoms or a breast lump that can be felt, typically being detected through screening mammography. It has been diagnosed in a significant percentage of men.

<span class="mw-page-title-main">Philip Strax</span> American physician

Philip Strax was an American radiologist who pioneered the use of mammography to screen for early breast cancer. With his co-investigators, the statistician Sam Shapiro and the surgeon Louis Venet, he conducted a randomized controlled trial comparing outcomes of over 60,000 women who received either mammogram and clinical breast exam or standard medical care. The first results of this study were published in the Journal of the American Medical Association (JAMA) in 1966. The study demonstrated that screening mammograms, which are routine periodic mammograms of asymptomatic women, could find breast cancer at an early enough stage to save lives. For this research Strax and Shapiro shared the Kettering Prize for outstanding contributions to cancer diagnosis or treatment in 1988.

<span class="mw-page-title-main">Lung cancer screening</span>

Lung cancer screening refers to cancer screening strategies used to identify early lung cancers before they cause symptoms, at a point where they are more likely to be curable. Lung cancer screening is critically important because of the incidence and prevalence of lung cancer. More than 235,000 new cases of lung cancer are expected in the United States in 2021 with approximately 130,000 deaths expected in 2021. In addition, at the time of diagnosis, 57% of lung cancers are discovered in advanced stages, meaning they are more widespread or aggressive cancers. Because there is a substantially higher probability of long-term survival following treatment of localized (60%) versus advanced stage (6%) lung cancer, lung cancer screening aims to diagnose the disease in the localized stage.

<span class="mw-page-title-main">Breast cancer screening</span> Medical screening of asymptomatic, healthy women for breast cancer

Breast cancer screening is the medical screening of asymptomatic, apparently healthy women for breast cancer in an attempt to achieve an earlier diagnosis. The assumption is that early detection will improve outcomes. A number of screening tests have been employed, including clinical and self breast exams, mammography, genetic screening, ultrasound, and magnetic resonance imaging.

<span class="mw-page-title-main">Cancer screening</span> Method to detect cancer

The objective of cancer screening is to detect cancer before symptoms appear, involving various methods such as blood tests, urine tests, DNA tests, and medical imaging. The purpose of screening is early cancer detection, to make the cancer easier to treat and extending life expectancy. In 2019, cancer was the second leading cause of death globally; more recent data is pending due to the COVID-19 pandemic.

A well-woman examination is an exam offered to women to review elements of their reproductive health. The exam includes a breast examination, a pelvic examination and a Pap smear but may include other procedures. Hospitals employ strict policies relating to the provision of consent by the patient, the availability of chaperones at the examination, and the absence of other parties.

Overscreening, also called unnecessary screening, is the performance of medical screening without a medical indication to do so. Screening is a medical test in a healthy person who is showing no symptoms of a disease and is intended to detect a disease so that a person may prepare to respond to it. Screening is indicated in people who have some threshold risk for getting a disease, but is not indicated in people who are unlikely to develop a disease. Overscreening is a type of unnecessary health care.

Cancer prevention is the practice of taking active measures to decrease the incidence of cancer and mortality. The practice of prevention is dependent upon both individual efforts to improve lifestyle and seek preventive screening, and socioeconomic or public policy related to cancer prevention. Globalized cancer prevention is regarded as a critical objective due to its applicability to large populations, reducing long term effects of cancer by promoting proactive health practices and behaviors, and its perceived cost-effectiveness and viability for all socioeconomic classes.

<span class="mw-page-title-main">H. Gilbert Welch</span> American doctor

H. Gilbert Welch is an American academic physician and cancer researcher. He was an internist at the Veterans Administration Medical Center in White River Junction, Vermont, as well as a professor of medicine at the Dartmouth Institute for Health Policy and Clinical Practice. In September 2018, Welch resigned from Dartmouth College after a 20-month long research misconduct investigation at Dartmouth concluded he had committed plagiarism.

<span class="mw-page-title-main">Breast imaging</span>

In medicine, breast imaging is a sub-speciality of diagnostic radiology that involves imaging of the breasts for screening or diagnostic purposes. There are various methods of breast imaging using a variety of technologies as described in detail below. Traditional screening and diagnostic mammography uses x-ray technology and has been the mainstay of breast imaging for many decades. Breast tomosynthesis is a relatively new digital x-ray mammography technique that produces multiple image slices of the breast similar to, but distinct from, computed tomography (CT). Xeromammography and galactography are somewhat outdated technologies that also use x-ray technology and are now used infrequently in the detection of breast cancer. Breast ultrasound is another technology employed in diagnosis and screening that can help differentiate between fluid filled and solid lesions, an important factor to determine if a lesion may be cancerous. Breast MRI is a technology typically reserved for high-risk patients and patients recently diagnosed with breast cancer. Lastly, scintimammography is used in a subgroup of patients who have abnormal mammograms or whose screening is not reliable on the basis of using traditional mammography or ultrasound.

Melissa Andrea Simon is an American clinical obstetrician/gynecologist and scientist who focuses on health equity across the lifespan. Simon is founder and director of the Center for Health Equity Transformation (CHET) in the Feinberg School of Medicine at Northwestern University in Chicago, Illinois, and founder of the Chicago Cancer Health Equity Collaborative, a National Cancer Institute comprehensive cancer partnership led by the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Northeastern Illinois University, and the University of Illinois at Chicago. She is the George H. Gardner, MD Professor of Clinical Gynecology, the Vice-Chair of Clinical Research in the Department of Obstetrics and Gynecology, tenured professor of Obstetrics and Gynecology, Preventive Medicine and Medical Social Sciences at Northwestern University Feinberg School of Medicine, and Associate Director of Community Outreach and Engagement at the Robert H. Lurie Comprehensive Cancer Center.

Dense breast tissue, also known as dense breasts, is a condition of the breasts where a higher proportion of the breasts are made up of glandular tissue and fibrous tissue than fatty tissue. Around 40–50% of women have dense breast tissue and one of the main medical components of the condition is that mammograms are unable to differentiate tumorous tissue from the surrounding dense tissue. This increases the risk of late diagnosis of breast cancer in women with dense breast tissue. Additionally, women with such tissue have a higher likelihood of developing breast cancer in general, though the reasons for this are poorly understood.

References

  1. ↑ "Clinical Guidelines and Recommendations". Agency for Healthcare Research Quality.
  2. ↑ "U.S. Preventive Services Task Force: About USPSTF". Agency for Healthcare Research Quality. November 2014.
  3. ↑ Selyukh, Alina (December 18, 2011). "Factbox: How the U.S. Preventive Services Task Force works". Reuters– via Yahoo News.
  4. ↑ "Methods and Processes". US Preventive Services Task Force. Retrieved 2015-10-22.
  5. ↑ Guirguis-Blake J, Calonge N, Miller T, Siu A, Teutsch S, Whitlock E (2007). "Current processes of the U.S. Preventive Services Task Force: refining evidence-based recommendation development". Ann. Intern. Med. 147 (2): 117–22. CiteSeerX   10.1.1.670.8563 . doi:10.7326/0003-4819-147-2-200707170-00170. PMID   17576998. S2CID   19346342.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  6. ↑ Barton MB, Miller T, Wolff T, et al. (2007). "How to read the new recommendation statement: methods update from the U.S. Preventive Services Task Force". Ann. Intern. Med. 147 (2): 123–7. doi:10.7326/0003-4819-147-2-200707170-00171. PMID   17576997.
  7. ↑ Pauly, Mark V.; Sloan, Frank A.; Sullivan, Sean D. (2014-11-01). "An Economic Framework For Preventive Care Advice". Health Affairs. 33 (11): 2034–2040. doi:10.1377/hlthaff.2013.0873. ISSN   0278-2715. PMID   25368000.
  8. ↑ Carroll, Aaron E. (2014-12-15). "Forbidden Topic in Health Policy Debate: Cost Effectiveness". The New York Times. ISSN   0362-4331 . Retrieved 2015-10-22.
  9. ↑ "Grade Definitions". US Preventive Services Task Force.
  10. ↑ "USPSTF A and B Recommendations by Date". US Preventive Services Task Force. Retrieved 2015-10-21.
  11. ↑ Davidson, Karina W.; Barry, Michael J.; Mangione, Carol M.; Cabana, Michael; Caughey, Aaron B.; Davis, Esa M.; Donahue, Katrina E.; Doubeni, Chyke A.; Krist, Alex H.; Kubik, Martha; Li, Li; Ogedegbe, Gbenga; Owens, Douglas K.; Pbert, Lori; Silverstein, Michael; Stevermer, James; Tseng, Chien-Wen; Wong, John B.; Wong, J. B. (2021). "Screening for Colorectal Cancer". JAMA. 325 (19): 1965–1977. doi: 10.1001/jama.2021.6238 . PMID   34003218. S2CID   234769050.
  12. ↑ US Preventive Services Task Force (November 2009). "Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement". Ann. Intern. Med. 151 (10): 716–26, W–236. doi:10.7326/0003-4819-151-10-200911170-00008. PMID   19920272.
  13. 1 2 "Screening for Breast Cancer: Recommendations and Rationale". Agency for Healthcare Research Quality. 2002.
  14. ↑ "Stat Fact Sheets: Cancer of the breast". SEER .
  15. ↑ Horner, MJ; Ries, LAG; Krapcho, M; et al. (2009). SEER Cancer Statistics Review, 1975-2006. SEER (Report). Bethesda, MD: National Cancer Institute.
  16. ↑ "Final Update Summary: Breast Cancer: Screening". US Preventive Services Task Force.
  17. ↑ Dellorto, Danielle. "Task force opposes routine mammograms for women age 40-49". CNN.
  18. ↑ "Role of evidence based medicine in clinical decision-making addressed by ACP in testimony". American College of Physicians. 2 December 2009.
  19. 1 2 Stubbs, Joseph W. (24 November 2009). "Statement On the Politicization of Evidence-based Clinical Research". American College of Physicians.
  20. 1 2 3 Walker, Emily (3 December 2009). "Senate Affirms Screening Mammography for 40-Year-Olds". ABC News. Retrieved 3 December 2009.
  21. 1 2 "Screening for Prostate Cancer Recommendation Statement". US Preventive Services Task Force. October 2022.
  22. 1 2 "Prostate Cancer: Screening: Screening". US Preventive Services Task. Retrieved 10 October 2022.
  23. ↑ "History Infographic EN" (PDF). canadiantaskforce.ca. 2020.
  24. ↑ "U.S. Preventive Services Task Force". Office of Disease Prevention and Health Promotion. Archived from the original on June 15, 2004.{{cite web}}: CS1 maint: unfit URL (link)
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.